NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve management of neovascular age-related macular degeneration (nAMD), diabetic macular edema, and pars planitis (PP). After hearing and assimilating this program, the clinician will be better able to:
1. Compare efficacy and durability of faricimab with first-generation anti-vascular endothelial growth factor therapies.
2. Discuss investigational therapies that offer extended durability or improved visual outcomes for retinal disease.
3. Analyze the advantages and disadvantages of various sustained drug delivery products for treatment of nAMD and diabetic retinopathy.
4. Conduct proper workup for uveitis based upon patient his-tory, symptoms, and examination findings.
5. Select appropriate therapy for PP.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Ophthalmology
- Start Date: 2022-11-30 06:00:00
- End Date: 2022-11-30 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABO - 2.0 Point; Credit Type(s): Lifelong Learning (ABO)
ABO - 2.0 Point; Credit Type(s): Self-Assessment (ABO) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Retina/Vitreous, Uveitis